Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Novartis’ siRNA Dyslipidemia Therapy and More Up for Panel Review on August 21
August 8, 2023
- MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
August 8, 2023
- Japan to Roll Out XBB-Tailored COVID Boosters on September 20
August 8, 2023
- Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
August 7, 2023
- Japan’s Healthcare Spending Up 11.0% in FY2021: IPSS Report
August 7, 2023
- Despite Increase in Reviewers, Japan Faces Backlog of Over 4,000 Health Damage Claims for COVID Jabs
August 4, 2023
- With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
- Japan to Set Up New Forum on Dementia Measures: PM
August 4, 2023
- 30% of Eligible Population Unaware of HPV Vaccine: Survey
August 4, 2023
- Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
- Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
- Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
- Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
August 3, 2023
- Relief Claims OK’ed for 38 More Deaths after COVID Vaccination
August 2, 2023
- Generics Panel Initiates Debate toward Proposing Stable Supply Measures, Interim Report Slated for October
August 1, 2023
- Pharma Regulation Panel to Discuss Need for PI Japanese Data on Aug. 7
August 1, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
- Japan Panel Shelves Decision on Shionogi’s COVID Vaccine over Efficacy Data
August 1, 2023
- First Two Homegrown COVID-19 Jabs Up for MHLW Panel Review on July 31
July 31, 2023
- Japan Safety Panels Recognize 2nd Death Possibly Linked to COVID Vaccine
July 31, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…